WESTON (dpa-AFX) – Biogen Inc. (BIIB) and Denali Therapeutics Inc. (DNLI) reported results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), a small molecule inhibitor of LRRK2 in early-st…
Biogen And Denali Stop BIIB122 Development After Phase 2b Parkinson’s Trial Shows No Benefit
Source: Finanznachrichten.de
Read Full Story →
